Conventional wisdom holds that, with the exception of skin and blood cells, most tissues in the body do not normally regenerate. But recent research has uncovered some surprising biological mechanisms that indicate that the body does in fact have the potential to repair some other vital tissues. Hoping to exploit this work, a Harvard University and University of Utah startup, Hydra BioSciences, is seeking to develop drugs that it says will repair damage from heart attacks.
Hydra’s focus is on heart attack survivors-a group joined by hundreds of thousands of people in the United States every year-who are often left with damaged, scarred cardiac tissue that could lead to complete heart failure later in life. Current drugs don’t repair the tissue, so Hydra is working on new treatments that will nudge mature heart-muscle cells to multiply again and ultimately form new, beating muscle. The three-year-old company’s first project is to develop drugs that would be given to patients within a few weeks after a heart attack to trigger regrowth of the healthy cells near the injured area and prevent the heart from weakening and scarring. A similar therapeutic strategy could eventually work for a wide range of ailments and injuries, such as type I diabetes, retinal degeneration, spinal-cord injury, and Parkinson’s disease, says Mark Keating, Hydra’s cofounder and a researcher at Children’s Hospital Boston.
In January, Hydra raised almost $19 million in second-round venture financing. And it has also made progress on discovering drug candidates. It recently isolated a protein that may stimulate cell growth in the heart and hopes to begin testing it in animals by the beginning of next year. “If this works, we can regenerate the heart and create newer, younger, better cells,” says Piero Anversa, director of the Cardiovascular Research Institute at the New York Medical College.
Anti-aging drugs are being tested as a way to treat covid
Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.
These materials were meant to revolutionize the solar industry. Why hasn’t it happened?
Perovskites are promising, but real-world conditions have held them back.
The baby formula shortage has birthed a shady online marketplace
Desperate parents just want to feed their babies. They’re having to contend with misinformation, price gouging, and scams along the way.
I tried to buy an Olive Garden NFT. All I got was heartburn.
Our newest issue spells out what you need to know about the dizzying world of digital money.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.